Burzynski Research Institute (BZYR) Net Cash Flow Growth (3y) (2013 - 2025)
Burzynski Research Institute (BZYR) Net Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -35.85% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 106.37% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 67.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -70.95% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 52.78% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.55% |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 42.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 42.55% |
| Aug 31, 2025 | 26.65% |
| May 31, 2025 | -26.39% |
| Feb 28, 2025 | 28.02% |
| Nov 30, 2024 | -28.54% |
| Aug 31, 2024 | 43.65% |
| May 31, 2024 | -57.46% |
| Feb 29, 2024 | 33.78% |
| Nov 30, 2023 | 8.99% |
| Aug 31, 2023 | -9.96% |
| May 31, 2023 | -68.94% |
| Feb 28, 2023 | -135.55% |
| Nov 30, 2022 | 35.36% |
| Aug 31, 2022 | -20.47% |
| May 31, 2022 | -16.79% |
| Feb 28, 2022 | -133.55% |
| Nov 30, 2021 | 298.21% |
| Aug 31, 2021 | 15.16% |
| May 31, 2021 | 55.68% |
| Feb 28, 2021 | 30.00% |